Shares in Senseonics (NYSE:SENS) have fallen slightly today after the continuous glucose monitoring-focused medtech company posted first quarter earnings that missed on earnings per share expectations but beat sales consensus on Wall Street.
The Germantown, Md.-based company posted losses of $22.3 million, or 16¢ per share, on sales of $2.9 million for the three months ended March 31, seeing losses grow 70.4% while sales grew 432.7% compared with the same period during the previous year.
Read the whole story on our sister site, Drug Delivery Business